PROVIDER STATEMENT

This activity is provided by Integrity CE, LLC.

DISCLOSURE OF COMMERCIAL SUPPORT

This activity is supported by an educational grant from Merck Sharp & Dohme, LLC.

PROGRAM OVERVIEW

Conventional medicine in inflammatory bowel disease (IBD) followed a one-or-two-treatments-fit-all approach. Treatment selection was simple, but outcomes were often poor, yielding no response or intolerable adverse effects. In 2025, a plethora of available treatments across many drug classes has made treatment selection, especially in the second-line, more complicated based on multiple patient variables. The advent of precision medicine takes advantage of new and emerging knowledge about prognostic and predictive biomarkers to more accurately presage disease severity and treatment response. Harnessing these tools to select and monitor response to existing and emerging treatments will enable gastroenterologists and other clinicians to help more patients with Crohn’s disease and ulcerative colitis to achieve clinical and endoscopic remission, yielding improved outcomes.

Join IBD expert Bruce E. Sands, MD, MS, AGAF for this virtual CME-accredited grand rounds activity on using precision medicine to optimize the management of IBD.

Optimizing IBD Outcomes: From Risk Stratification to Therapeutic Monitoring in the Era of Precision Medicine - Thursday, February 5, 2026